Shares of Lupin Ltd dropped 6.27% to ₹1,964.40 on Friday, down ₹131.30 from the previous close of ₹2,095.70, after reports stated that U.S. President Donald Trump and his administration is considering imposing tariffs on pharmaceutical imports.
Although pharmaceutical products were temporarily exempt from the earlier round of reciprocal tariffs, Trump’s fresh remarks on Air Force One signaled renewed risks. “Pharma tariffs are going to come in at levels you haven’t really seen before. We are looking at pharmaceuticals as a separate category. We will be announcing that sometime in the near-future and not too distant future. It’s under review right now,” he said.
The news has triggered fresh concerns among investors, especially for Indian pharma exporters like Lupin, which derive a significant portion of their revenues from the U.S. market. Despite earlier relief when the sector escaped the initial tariff list, the possibility of future trade restrictions has cast a shadow on sentiment.
Trump’s remarks follow months of speculation, with earlier suggestions of a 25% levy on medicine imports. While no final decision has been made, the uncertainty continues to pressure pharma stocks globally.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Please consult your financial advisor before making any investment decisions.
